Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?

Expert Rev Anti Infect Ther. 2016;14(1):41-56. doi: 10.1586/14787210.2016.1114883. Epub 2015 Dec 14.

Abstract

This review summarizes published data on sofosbuvir-based regimens for patients infected with HCV GT1 with a focus on evaluating the optimal and possible durations of treatment.

Methods: PubMed and conference abstract books published between 2011-2015 were searched.

Results: HCV treatment has decreased from 24 week regimens to studies done as short as 4 weeks. History of prior treatment or cirrhosis have consistently shown lower SVR12 rates with shorter duration therapies. Low cure rates have been seen in patients within 4 week trials, however, select patients with low fibrosis scores, low HCV VL and HCV GT-1b have moderate cure rates.

Conclusion: Most patients will require 12-24 weeks of therapy. Further studies are needed to elucidate the predictors of treatment response to short duration therapies and optimal combination of DAAs.

Keywords: (5-10): sofosbuvir; IFN free regimens; NS5B inhibitor; directly acting antivirals; duration; genotype 1; hepatitis C.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Disease Management
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Fluorenes / therapeutic use
  • Genotype
  • Hepacivirus / drug effects*
  • Hepacivirus / pathogenicity
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / prevention & control*
  • Liver Cirrhosis / virology
  • RNA, Viral / antagonists & inhibitors*
  • RNA, Viral / biosynthesis
  • Ribavirin / therapeutic use
  • Sofosbuvir / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • RNA, Viral
  • ledipasvir
  • Ribavirin
  • Sofosbuvir